Hot Features
プレミアム
Tourmaline Bio Inc (TRML)
NASDAQ
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and ... Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. 詳細を表示
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD...
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.66 | -7.44060959211 | 22.31 | 22.8 | 19.14 | 178093 | 21.24741916 | CS |
| 4 | -2.04 | -8.99074482151 | 22.69 | 26.78 | 19.14 | 187634 | 23.4959582 | CS |
| 12 | -4.61 | -18.2501979414 | 25.26 | 29.7883 | 19.14 | 212744 | 25.6187422 | CS |
| 26 | 5.15 | 33.2258064516 | 15.5 | 29.7883 | 12.12 | 205479 | 21.13733343 | CS |
| 52 | 1.45 | 7.55208333333 | 19.2 | 48.31 | 12.12 | 271435 | 23.51530937 | CS |
| 156 | 10.33 | 100.096899225 | 10.32 | 48.31 | 9.18 | 248894 | 23.12428422 | CS |
| 260 | 10.33 | 100.096899225 | 10.32 | 48.31 | 9.18 | 248894 | 23.12428422 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
